美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Veraxa Biotech Holding AG

9.46

-11.8000-55.50%

盤前：7.78-1.6756-17.71%05:28 EDT

成交量：56.29萬

成交額：600.50萬

市值：15.51億

市盈率：44.16

高：21.57

開：21.57

低：7.82

收：21.26

52周最高：27.36

52周最低：7.82

股本：1.64億

流通股本：1.58億

量比：14.38

換手率：0.36%

股息：- -

股息率：- -

每股收益(TTM):0.2142

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Veraxa Biotech Holding AG

交易所：

NASDAQ

成立時間：

2021

員工人數：

- -

公司地址：

Im Neuenheimer Feld 584,Heidelberg,Baden-Württemberg,Germany

官網：

http://www.veraxa.com

郵編：

69120

電話：

49 6221 3521330

傳真：

- -

簡介：

Veraxa Biotech AG是一家根據瑞士法律成立的股份有限公司。該公司是一家專註於腫瘤治療的生物技術公司，總部位於瑞士蘇黎世，致力於推進新型抗體藥物平台在癌症治療領域的研發。公司的技術源於歐洲分子生物學實驗室的科學發現。Veraxa Biotech AG的專有平台技術旨在開發新一代靶向抗體癌症療法，從而加速下一代癌症治療方案的研發，並有望通過提高安全性和有效性，拓寬目前實體瘤標準療法的治療窗口。

董事

名稱

職位

Adeel Rouf

President, Chief Executive Officer and Director

Warren Hosseinion

Chairman of the Board and Director

Jonathan Intrater

Independent Director

Oded Levy

Independent Director

股東

名稱

職位

Adeel Rouf

President, Chief Executive Officer and Director

Alex Rogers

Chief Financial Officer

Warren Hosseinion Jr.

Vice President, Mergers and Acquisitions

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/VRXA/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VRXA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","market":"US","secType":"STK","nameCN":"Veraxa Biotech Holding AG","latestPrice":9.46,"timestamp":1781640000000,"preClose":21.26,"halted":0,"volume":562873,"hourTrading":{"tag":"盘前","latestPrice":7.7844,"preClose":9.46,"latestTime":"05:28 EDT","volume":2011,"amount":16699.378187,"timestamp":1781688519692,"change":-1.6756,"changeRate":-0.177125,"amplitude":0.096195},"delay":0,"changeRate":-0.555032925682032,"floatShares":158000000,"shares":164000000,"eps":0.2142,"marketStatus":"盤前交易","change":-11.8,"latestTime":"06-17 05:29:29 EDT","open":21.57,"high":21.57,"low":7.82,"amount":6005034.241166,"amplitude":0.646754,"askPrice":8.79,"askSize":100,"bidPrice":7.75,"bidSize":200,"shortable":0,"etf":0,"ttmEps":0.2142,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1781703000000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":9.46,"preHourTrading":{"tag":"盘前","latestPrice":7.7844,"preClose":9.46,"latestTime":"05:28 EDT","volume":2011,"amount":16699.378187,"timestamp":1781688519692,"change":-1.6756,"changeRate":-0.177125,"amplitude":0.096195},"postHourTrading":{"tag":"盘后","latestPrice":8.5,"preClose":9.46,"latestTime":"19:59 EDT","volume":18898,"amount":165176.4188,"timestamp":1781654369215,"change":-0.96,"changeRate":-0.10148,"amplitude":0.27907},"volumeRatio":14.376162962228134},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","floatShares":158000000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":14.376162962228134,"shares":164000000,"dividePrice":0,"high":21.57,"amplitude":0.646754,"preClose":21.26,"low":7.82,"week52Low":7.82,"pbRate":"--","week52High":27.36,"institutionHeld":0,"latestPrice":9.46,"committee":0.333333,"eps":0.2142,"divideRate":0,"volume":562873,"delay":0,"ttmEps":0.2142,"open":21.57,"prevYearClose":18.65,"prevWeekClose":20,"prevMonthClose":18.65,"prevQuarterClose":18.65},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VRXA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VRXA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":699307581,"yearFounded":2021,"address":"Im Neuenheimer Feld 584,Heidelberg,Baden-Württemberg,Germany","zipCode":"69120","officePhone":"49 6221 3521330"},"stockCompanyDetail":{"websiteUrl":"http://www.veraxa.com","stockEarnings":[{"period":"1week","weight":-0.4928},{"period":"ytd","weight":-0.4928}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.0151},{"period":"3month","weight":0.1344},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.245},{"period":"ytd","weight":0.1003}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Veraxa Biotech AG是一家根據瑞士法律成立的股份有限公司。該公司是一家專註於腫瘤治療的生物技術公司，總部位於瑞士蘇黎世，致力於推進新型抗體藥物平台在癌症治療領域的研發。公司的技術源於歐洲分子生物學實驗室的科學發現。Veraxa Biotech AG的專有平台技術旨在開發新一代靶向抗體癌症療法，從而加速下一代癌症治療方案的研發，並有望通過提高安全性和有效性，拓寬目前實體瘤標準療法的治療窗口。","exchange":"NASDAQ","name":"Veraxa Biotech Holding AG","nameEN":"Veraxa Biotech Holding AG"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":{"directors":[{"name":"Adeel Rouf","position":"President, Chief Executive Officer and Director"},{"name":"Warren Hosseinion","position":"Chairman of the Board and Director"},{"name":"Jonathan Intrater","position":"Independent Director"},{"name":"Oded Levy","position":"Independent Director"}],"executives":[{"name":"Adeel Rouf","position":"President, Chief Executive Officer and Director"},{"name":"Alex Rogers","position":"Chief Financial Officer"},{"name":"Warren Hosseinion Jr.","position":"Vice President, Mergers and Acquisitions"}]}}}